{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T06:10:41Z","timestamp":1793427041920,"version":"4.5.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.025","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T18:04:38Z","timestamp":1676397878000},"page":"1934-1942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis"],"prefix":"10.1016","volume":"41","author":[{"given":"Muhammad Taufeeq","family":"Wahab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayner Kay Jin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0528-798X","authenticated-orcid":false,"given":"Kiesha","family":"Prem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.02.025_b0005","unstructured":"Human papillomavirus vaccines: WHO position paper [Internet]. 2017 [cited 2021 Oct 14]. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/policies\/position-papers\/human-papillomavirus-(hpv)."},{"key":"10.1016\/j.vaccine.2023.02.025_b0010","unstructured":"World Health Organization. Health topics: cervical cancer [Internet]. 2021 [cited 2021 Oct 14]. Available from: https:\/\/www.who.int\/health-topics\/cervical-cancer#tab=tab_1."},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.025_b0015","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4108-y","article-title":"Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK","volume":"19","author":"Datta","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.025_b0020","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(14)71073-4","article-title":"Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis","volume":"15","author":"Drolet","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.025_b0025","article-title":"HPV: WHO calls for countries to suspend vaccination of boys","volume":"2","author":"Arie","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2023.02.025_b0030","unstructured":"Singapore cancer registry 50th anniversary monograph 1968-2017. 2019."},{"key":"10.1016\/j.vaccine.2023.02.025_b0035","unstructured":"Total Net Enrolment Rate for Primary and Secondary Education [Internet]. Data.gov.sg. [cited 2021 Oct 14]. Available from: https:\/\/data.gov.sg\/dataset\/net-enrolment-ratio-for-primary-and-secondary-education?view_id=ab69441f-951a-4d99-9b31-735fa8530121&resource_id=7b184af5-b718-4c93-b217-c3bb3ab304f4."},{"key":"10.1016\/j.vaccine.2023.02.025_b0040","unstructured":"Yam A, Khor ALS. Misinformation regarding medical and social effects of HPV vaccination [Internet]. Singapore Parliamentary Question. 2019. Available from: https:\/\/www.parliament.gov.sg."},{"issue":"16","key":"10.1016\/j.vaccine.2023.02.025_b0045","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.vaccine.2021.03.040","article-title":"Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore","volume":"39","author":"Phua","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.025_b0050","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/1471-0528.15106","article-title":"Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis","volume":"125","author":"Tay","year":"2018","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.025_b0055","doi-asserted-by":"crossref","first-page":"370","DOI":"10.11622\/smedj.2017085","article-title":"Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore","volume":"59","author":"Tay","year":"2018","journal-title":"Singapore Med J"},{"key":"10.1016\/j.vaccine.2023.02.025_b0060","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2458-11-203","article-title":"Cost-effectiveness of different human papillomavirus vaccines in Singapore","volume":"11","author":"Lee","year":"2011","journal-title":"BMC Public Health"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.025_b0065","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1016\/S2214-109X(14)70237-2","article-title":"Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study","volume":"2","author":"Jit","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2023.02.025_b0070","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25973","article-title":"Application of the network scale-up method to estimate the sizes of key populations for HIV in Singapore using online surveys","author":"Quaye","year":"2023","journal-title":"J Int AIDS Soc"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.025_b0075","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2468-2667(16)30001-9","article-title":"Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models","volume":"1","author":"Brisson","year":"2016","journal-title":"Lancet Public Health"},{"key":"10.1016\/j.vaccine.2023.02.025_b0080","unstructured":"Statement on HPV vaccination - Joint Committee on Vaccination and Immunisation [Internet]. London; 2018. Available from: www.nationalarchives.gov.uk\/doc\/open-government-licence\/."},{"issue":"3","key":"10.1016\/j.vaccine.2023.02.025_b0085","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/jir285","article-title":"Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity","volume":"204","author":"Brisson","year":"2011","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.02.025_b0090","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1002\/ijc.22527","article-title":"Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update","volume":"121","author":"Smith","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2023.02.025_b0095","doi-asserted-by":"crossref","unstructured":"Jit M, Chapman R, Hughes O, Choi YH. Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model. BMJ 2011;343(sep27 1):d5775.","DOI":"10.1136\/bmj.d5775"},{"issue":"8","key":"10.1016\/j.vaccine.2023.02.025_b0100","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/jnci\/djt053","article-title":"Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study","volume":"105","author":"Anantharaman","year":"2013","journal-title":"JNCI: J Natl Cancer Inst"},{"issue":"8","key":"10.1016\/j.vaccine.2023.02.025_b0105","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2023.02.025_b0110","unstructured":"Cancer Research UK. Cancer incidence statistics [Internet]. [cited 2022 Jun 23]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence."},{"key":"10.1016\/j.vaccine.2023.02.025_b0115","unstructured":"Cancer Research UK. Cancer mortality statistics [Internet]. [cited 2022 Jun 23]. Available from: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/mortality."},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.025_b0120","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/cncr.20365","article-title":"Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer","volume":"101","author":"Daling","year":"2004","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.vaccine.2023.02.025_b0125","doi-asserted-by":"crossref","first-page":"e0184623","DOI":"10.1371\/journal.pone.0184623","article-title":"Prevalence and determinants of oral infection by Human Papillomavirus in HIV-infected and uninfected men who have sex with men","volume":"12","author":"Rollo","year":"2017","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.vaccine.2023.02.025_b0130","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000845","article-title":"Risk factors for oral human papillomavirus infection among young men who have sex with men\u20142 cities, United States, 2012\u20132014","volume":"45","author":"Oliver","year":"2018","journal-title":"Sex Transm Dis"},{"issue":"16","key":"10.1016\/j.vaccine.2023.02.025_b0135","doi-asserted-by":"crossref","first-page":"8500","DOI":"10.3390\/ijerph18168500","article-title":"Impact of sexual activity on the risk of male genital tumors: a systematic review of the literature","volume":"18","author":"Crocetto","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.vaccine.2023.02.025_b0140","first-page":"S43","article-title":"Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynecol Obstet"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.025_b0145","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/sextrans-2011-050161","article-title":"Quality of life valuations of HPV-associated cancer health states by the general population","volume":"88","author":"Conway","year":"2012","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.vaccine.2023.02.025_b0150","unstructured":"Myers E, Green S, Lipkus I. Patient preferences for health states related to HPV infection: visual analogue scales vs. time trade-off elicitation. In: Proceedings of the 21st international papillomavirus conference. Mexico City; 2004."},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.025_b0155","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1136\/sextrans-2018-053606","article-title":"Systematic review and evidence synthesis of non-cervical human papillomavirus-related disease health system costs and quality of life estimates","volume":"95","author":"Ong","year":"2019","journal-title":"Sex Transm Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.025_b0160","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1017\/S0266462319000114","article-title":"Cost-effectiveness of pain management strategies in advanced cancer","volume":"35","author":"Meads","year":"2019","journal-title":"Int J Technol Assess Health Care"},{"issue":"9","key":"10.1016\/j.vaccine.2023.02.025_b0165","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1177\/0269216315578803","article-title":"Comparison of preferences for end-of-life care among patients with advanced cancer and their caregivers: a discrete choice experiment","volume":"29","author":"Malhotra","year":"2015","journal-title":"Palliat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.025_b0170","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1158\/1055-9965.EPI-20-1230","article-title":"Cost-effectiveness analysis of breast cancer screening using mammography in Singapore: a modeling study","volume":"30","author":"Chootipongchaivat","year":"2021","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"10.1016\/j.vaccine.2023.02.025_b0175","unstructured":"Agency for Care Effectiveness (ACE). Drug and vaccine evaluation methods and process guide. Singapore; 2021."},{"key":"10.1016\/j.vaccine.2023.02.025_b0180","doi-asserted-by":"crossref","unstructured":"Linertov\u00e1 R, Guirado-Fuentes C, Mar Medina J, Imaz-Iglesia I, Rodr\u00edguez-Rodr\u00edguez L, Carmona-Rodr\u00edguez M. Cost-effectiveness of extending the HPV vaccination to boys: a systematic review. J Epidemiol Community Health (1978). 2021;75(9):910\u20136.","DOI":"10.1136\/jech-2020-216305"},{"key":"10.1016\/j.vaccine.2023.02.025_b0185","unstructured":"U.S. Food & Drug Administration. Cervarix [Internet]. 2019 [cited 2022 Jun 27]. Available from: https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/cervarix."},{"key":"10.1016\/j.vaccine.2023.02.025_b0190","unstructured":"European Medicines Agency. Cervarix [Internet]. 2022 [cited 2022 Jun 27]. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/cervarix#authorisation-details-section."},{"issue":"9","key":"10.1016\/j.vaccine.2023.02.025_b0195","doi-asserted-by":"crossref","first-page":"e531","DOI":"10.1016\/S2352-3018(21)00108-9","article-title":"Epidemiology of anal human papillomavirus infection and high-grade squamous intraepithelial lesions in 29 900 men according to HIV status, sexuality, and age: a collaborative pooled analysis of 64 studies","volume":"8","author":"Wei","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.vaccine.2023.02.025_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2021.754112","article-title":"Human papillomavirus vaccine course completion among gay and bisexual men who have sex with men from a time-limited HPV vaccination catch-up program in Victoria, Australia","volume":"9","author":"Htaik","year":"2021","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.025_b0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13011-021-00353-2","article-title":"Social capital and chemsex initiation in young gay, bisexual, and other men who have sex with men: the pink carpet Y cohort study","volume":"16","author":"Tan","year":"2021","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.025_b0210","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1186\/s12889-021-10992-6","article-title":"Association between sexual orientation acceptance and suicidal ideation, substance use, and internalised homophobia amongst the pink carpet Y cohort study of young gay, bisexual, and queer men in Singapore","volume":"21","author":"Ong","year":"2021","journal-title":"BMC Public Health"},{"issue":"41","key":"10.1016\/j.vaccine.2023.02.025_b0215","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.41.1700737","article-title":"The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?","volume":"23","author":"Patel","year":"2018","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2023.02.025_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2020.100195","article-title":"IPVS statement on \u201cTemporary HPV vaccine shortage: implications globally to achieve equity\u201d","volume":"9","author":"Garland","year":"2020","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.vaccine.2023.02.025_b0225","unstructured":"Basu P, Brisson M, Campos N, Clarke E, Drolet M, Gallagher KE, et al. Review of the current published evidence on single-dose HPV vaccination. 3rd edition. London School of Hygiene & Tropical Medicine; 2020."},{"issue":"10","key":"10.1016\/j.vaccine.2023.02.025_b0230","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/jnci\/djaa011","article-title":"Evaluation of durability of a single dose of the bivalent HPV vaccine: the CVT trial","volume":"112","author":"Kreimer","year":"2020","journal-title":"JNCI: J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2023.02.025_b0235","unstructured":"Ministry of Health. Release of new screening test review committee guidelines, including changes to diabetes mellitus, lipid disorders, and cervical cancer screening. Singapore; 2019."},{"key":"10.1016\/j.vaccine.2023.02.025_b0240","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1469-0691.2012.03977.x","article-title":"Economic evaluation of vaccination: capturing the full benefits, with an application to human papillomavirus","volume":"18","author":"B\u00e4rnighausen","year":"2012","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.025_b0245","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2165\/11539960-000000000-00000","article-title":"Modelling the epidemiology of infectious diseases for decision analysis","volume":"29","author":"Jit","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2023.02.025_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.pvr.2019.100184","article-title":"HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control","volume":"8","author":"Canfell","year":"2019","journal-title":"Papillomavirus Research"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:06Z","timestamp":1759404306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":50,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001603"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}